Differentiate an Investigational New Drug (IND) application from a New Drug Application (NDA) and a Biologics License Application (BLA) in terms of purpose and content?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Understanding how IND, NDA, and BLA fit together in the drug development pathway is about when each is used and what information it contains. An Investigational New Drug application is the permission to begin testing a product in humans. It is built from preclinical safety data, information about how the drug is made and controlled (the manufacturing data), and a detailed plan for the planned clinical trials. Its purpose is to protect participants by ensuring that human studies can be conducted safely and under a clear protocol; it does not approve the product for sale.

After the clinical program shows safety and efficacy, a sponsor submits a New Drug Application for small-molecule drugs or a Biologics License Application for biologics to request marketing authorization. These applications compile the full body of evidence from the clinical trials, plus comprehensive manufacturing quality data, labeling, and post-market commitments, so the FDA can decide whether the product can be marketed. Biologics—such as vaccines and many gene therapies—fall under the BLA pathway, while typical chemical drugs fall under the NDA pathway. The key difference is that INDs authorize human testing, whereas NDAs and BLAs authorize bringing a product to patients on the market.